CoChat

Rapamycin affects early fracture healing in mice

Open access
Holstein, J H, Klein, M, Garcia, P, Histing, T, Culemann, U, Pizanis, A, Laschke, M W, Scheuer, C, Meier, C, Schorr, H, Pohlemann, T, Menger, M D · 2008 · British Journal of Pharmacology
Cited by 71

The DOI matches its Crossref record.

Abstract

Background and purpose: The immunosuppressive drug rapamycin (RAPA) prevents rejection in organ transplantation by inhibiting interleukin‐2‐stimulated T‐cell division. Rapamycin has also been suggested to possess strong anti‐angiogenic activities linked to a decrease in production of vascular endothelial growth factor (VEGF). Angiogenesis and VEGF are thought to play a crucial role in fracture healing and as osteoporotic and traumatic fractures are common complications in immunosuppressed, organ transplantation patients, we conducted this study to analyze the effect of rapamycin treatment on bone repair. Experimental approach: We investigated the effect of rapamycin treatment on bone repair in a murine closed femur fracture model using radiological, histomorphometric, immunohistochemical, biomechanical and protein biochemical analyses. Key results: X‐ray analyses demonstrated that rapamycin treatment inhibits callus formation after two weeks of fracture healing. The radiologically observed lack of callus formation was confirmed by histomorphometric analyses, which revealed a significantly diminished callus size and a reduced amount of bone formation when compared with vehicle‐treated controls. Biomechanical testing further demonstrated that rapamycin significantly reduces torsional stiffness of the callus. Interestingly, this effect was associated with decreased vessel formation; a diminished proliferation of osteoblasts, endothelial cells and periosteal cells; and a reduced VEGF expression in hypertrophic chondrocytes. After five weeks treatment, however, the negative impact of rapamycin on fracture healing was overcome. Conclusions and implications: Thus, rapamycin initially delays fracture healing, most probably by inhibiting cell proliferation and neovascularization in the callus. These undesirable effects should be considered when rapamycin is administered to patients sustaining bone fractures. British Journal of Pharmacology (2008) 154, 1055–1062; doi:10.1038/bjp.2008.167; published online 5 May 2008

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/bjp.2008.167

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

Metadata

Authors
Holstein, J. H., Klein, M., Garcia, P., Histing, T., Culemann, U., Pizanis, A., Laschke, M. W., Scheuer, C., Meier, C., Schorr, H., Pohlemann, T., & Menger, M. D.
Venue
British Journal of Pharmacology
Publisher
Wiley
Published
2008-07
Volume
154
Issue
5
Pages
1055-1062
ISSN
  • 0007-1188 (ISSN-L)
  • 1476-5381
OpenAlex
W2062368370
Cited by
71
References
0
FWCI
3.28
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.